Skip to main content

Main menu

  • Home
  • Content
    • Current
    • Ahead of print
    • Past Issues
    • JNM Supplement
    • SNMMI Annual Meeting Abstracts
    • Continuing Education
    • JNM Podcasts
  • Subscriptions
    • Subscribers
    • Institutional and Non-member
    • Rates
    • Journal Claims
    • Corporate & Special Sales
  • Authors
    • Submit to JNM
    • Information for Authors
    • Assignment of Copyright
    • AQARA requirements
  • Info
    • Reviewers
    • Permissions
    • Advertisers
  • About
    • About Us
    • Editorial Board
    • Contact Information
  • More
    • Alerts
    • Feedback
    • Help
    • SNMMI Journals
  • SNMMI
    • JNM
    • JNMT
    • SNMMI Journals
    • SNMMI

User menu

  • Subscribe
  • My alerts
  • Log in
  • My Cart

Search

  • Advanced search
Journal of Nuclear Medicine
  • SNMMI
    • JNM
    • JNMT
    • SNMMI Journals
    • SNMMI
  • Subscribe
  • My alerts
  • Log in
  • My Cart
Journal of Nuclear Medicine

Advanced Search

  • Home
  • Content
    • Current
    • Ahead of print
    • Past Issues
    • JNM Supplement
    • SNMMI Annual Meeting Abstracts
    • Continuing Education
    • JNM Podcasts
  • Subscriptions
    • Subscribers
    • Institutional and Non-member
    • Rates
    • Journal Claims
    • Corporate & Special Sales
  • Authors
    • Submit to JNM
    • Information for Authors
    • Assignment of Copyright
    • AQARA requirements
  • Info
    • Reviewers
    • Permissions
    • Advertisers
  • About
    • About Us
    • Editorial Board
    • Contact Information
  • More
    • Alerts
    • Feedback
    • Help
    • SNMMI Journals
  • View or Listen to JNM Podcast
  • Visit JNM on Facebook
  • Join JNM on LinkedIn
  • Follow JNM on Twitter
  • Subscribe to our RSS feeds
Research ArticleClinical Investigations

Optimal Acquisition Time Window and Simplified Quantification of Dopamine Transporter Availability Using 18F-FE-PE2I in Healthy Controls and Parkinson Disease Patients

Ida Sonni, Patrik Fazio, Martin Schain, Christer Halldin, Per Svenningsson, Lars Farde and Andrea Varrone
Journal of Nuclear Medicine October 2016, 57 (10) 1529-1534; DOI: https://doi.org/10.2967/jnumed.115.171231
Ida Sonni
1Karolinska Institutet, Department of Clinical Neuroscience, Centre for Psychiatry Research, Stockholm, Sweden
2Sapienza University of Rome, Department of Medical-Surgical Sciences and of Translational Medicine, Nuclear Medicine Unit, Rome, Italy
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Patrik Fazio
1Karolinska Institutet, Department of Clinical Neuroscience, Centre for Psychiatry Research, Stockholm, Sweden
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Martin Schain
1Karolinska Institutet, Department of Clinical Neuroscience, Centre for Psychiatry Research, Stockholm, Sweden
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Christer Halldin
1Karolinska Institutet, Department of Clinical Neuroscience, Centre for Psychiatry Research, Stockholm, Sweden
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Per Svenningsson
3Karolinska Institutet, Department of Clinical Neuroscience, Centre for Molecular Medicine, Stockholm, Sweden; and
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Lars Farde
1Karolinska Institutet, Department of Clinical Neuroscience, Centre for Psychiatry Research, Stockholm, Sweden
4AstraZeneca Translational Science Centre at Karolinska Institutet, PET CoE, Stockholm, Sweden
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Andrea Varrone
1Karolinska Institutet, Department of Clinical Neuroscience, Centre for Psychiatry Research, Stockholm, Sweden
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • Article
  • Figures & Data
  • Supplemental
  • Info & Metrics
  • PDF
Loading

Article Figures & Data

Figures

  • Tables
  • Additional Files
  • FIGURE 1.
    • Download figure
    • Open in new tab
    • Download powerpoint
    FIGURE 1.

    HRRT average image (A) and HR average image (B) obtained using selected optimal acquisition time window. Axial images are at level of striatum and midbrain (SN).

  • FIGURE 2.
    • Download figure
    • Open in new tab
    • Download powerpoint
    FIGURE 2.

    Linear regression analysis of WAPI BPND and SBR calculated on average images obtained using selected time window (from min 16.5 to 42), on HRRT and simulated HR systems.

  • FIGURE 3.
    • Download figure
    • Open in new tab
    • Download powerpoint
    FIGURE 3.

    Linear regression analysis of WAPI BPND and SBRHR in controls and PD patients. SBRHR was obtained from average images using selected time window.

  • FIGURE 4.
    • Download figure
    • Open in new tab
    • Download powerpoint
    FIGURE 4.

    Linear regression analysis of SBRHR and WAPI BPND for controls (A) and PD patients (B) in all regions examined. SBRHR was obtained from average images using selected time window.

Tables

  • Figures
  • Additional Files
    • View popup
    TABLE 1

    Demographic and Clinical Data of Controls and PD Patients

    GroupAgeSexMMSEDisease duration (y)H-Y stageUPDRS motorLEDs
    Controls60.3 ± 79 M/1F29.4 ± 1NANANANA
    PD patients60.2 ± 99 M/1F28.7 ± 13.1 ± 41.418.9 ± 7348.6 ± 268
    • Data are mean ± SD.

    • MMSE = Mini-Mental State Examination; H-Y stage = Hoehn and Yahr stage; UPDRS = Unified Parkinson's Disease Rating Scale; LED = Levodopa-equivalent dose; NA = not applicable.

    • View popup
    TABLE 2

    WAPI BPND and SBRdyn Correlation for 8 Different Time Windows

    Time window (min)r2Linear regression equation (WAPI BPND – SBRdyn)Difference between outcome measures in Bland–Altman plots (mean ± SD)Bland–Altman plot slope (WAPI BPND – SBRdyn)
    SBR I (16.5–42)0.98y = 0.85x + 0.210.13 ± 0.290.15
    SBR II (42–66)0.97y = 1.47x + 0.03−1.06 ± 0.80−0.40
    SBR III (66–90)0.90y = 1.60x + 0.33−1.08 ± 1.18−0.52
    SBR IV (10.5–19.5)0.91y = 0.44x + 0.161.25 ± 0.880.81
    SBR V (19.5–30)0.97y = 0.74x + 0.250.36 ± 0.430.29
    SBR VI (30–42)0.99y = 1.13x + 0.21−0.52 ± 0.32−0.14
    SBR VII (13.5–36)0.97y = 0.70x + 0.210.50 ± 0.480.34
    SBR VIII (13.5–42)0.98y = 0.78x + 0.190.31 ± 0.370.23
    • r2 = linear regression equation, difference between outcome measures in Bland–Altman plots and slope of Bland–Altman plots.

    • View popup
    TABLE 3

    Percentage Difference Between WAPI BPND and SBR values (SBRHRRT and SBRHR) in Controls and PD Patients

    ControlsPD patients
    % differenceSBRHRRTSBRHRSBRHRRTSBRHR
    Caudate18.0%40.0%15.4%38.4%
    Putamen20.8%36.0%6.4%19.4%
    Ventral striatum16.5%34.5%11.6%30.4%
    SN−5.1%22.3%−11.2%14.6%
    • View popup
    TABLE 4

    Cohen Effect Size for All ROIs

    Effect sizeCaudatePutamenVentral striatumSN
    SBRHRRT0.601.480.660.38
    SBRHR0.561.400.630.38
    WAPI BPND0.651.700.690.49
    SRTM0.661.600.620.53
    LoganRef0.621.570.610.49

Additional Files

  • Figures
  • Tables
  • Supplemental Data

    Files in this Data Supplement:

    • Supplemental Data
PreviousNext
Back to top

In this issue

Journal of Nuclear Medicine: 57 (10)
Journal of Nuclear Medicine
Vol. 57, Issue 10
October 1, 2016
  • Table of Contents
  • Table of Contents (PDF)
  • About the Cover
  • Index by author
Print
Download PDF
Article Alerts
Sign In to Email Alerts with your Email Address
Email Article

Thank you for your interest in spreading the word on Journal of Nuclear Medicine.

NOTE: We only request your email address so that the person you are recommending the page to knows that you wanted them to see it, and that it is not junk mail. We do not capture any email address.

Enter multiple addresses on separate lines or separate them with commas.
Optimal Acquisition Time Window and Simplified Quantification of Dopamine Transporter Availability Using 18F-FE-PE2I in Healthy Controls and Parkinson Disease Patients
(Your Name) has sent you a message from Journal of Nuclear Medicine
(Your Name) thought you would like to see the Journal of Nuclear Medicine web site.
Citation Tools
Optimal Acquisition Time Window and Simplified Quantification of Dopamine Transporter Availability Using 18F-FE-PE2I in Healthy Controls and Parkinson Disease Patients
Ida Sonni, Patrik Fazio, Martin Schain, Christer Halldin, Per Svenningsson, Lars Farde, Andrea Varrone
Journal of Nuclear Medicine Oct 2016, 57 (10) 1529-1534; DOI: 10.2967/jnumed.115.171231

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero
Share
Optimal Acquisition Time Window and Simplified Quantification of Dopamine Transporter Availability Using 18F-FE-PE2I in Healthy Controls and Parkinson Disease Patients
Ida Sonni, Patrik Fazio, Martin Schain, Christer Halldin, Per Svenningsson, Lars Farde, Andrea Varrone
Journal of Nuclear Medicine Oct 2016, 57 (10) 1529-1534; DOI: 10.2967/jnumed.115.171231
Twitter logo Facebook logo LinkedIn logo Mendeley logo
  • Tweet Widget
  • Facebook Like
  • Google Plus One
Bookmark this article

Jump to section

  • Article
    • Abstract
    • MATERIALS AND METHODS
    • RESULTS
    • DISCUSSION
    • CONCLUSION
    • DISCLOSURE
    • Acknowledgments
    • Footnotes
    • REFERENCES
  • Figures & Data
  • Supplemental
  • Info & Metrics
  • PDF

Related Articles

  • This Month in JNM
  • PubMed
  • Google Scholar

Cited By...

  • Whole-Body Biodistribution and Dosimetry of the Dopamine Transporter Radioligand 18F-FE-PE2I in Human Subjects
  • Google Scholar

More in this TOC Section

  • Feasibility of Ultra-Low-Activity 18F-FDG PET/CT Imaging Using a Long–Axial-Field-of-View PET/CT System
  • Cardiac Presynaptic Sympathetic Nervous Function Evaluated by Cardiac PET in Patients with Chronotropic Incompetence Without Heart Failure
  • Validation and Evaluation of a Vendor-Provided Head Motion Correction Algorithm on the uMI Panorama PET/CT System
Show more Clinical Investigations

Similar Articles

Keywords

  • dopamine transporter
  • PET
  • Parkinson disease
  • FE-PE2I
  • quantification
SNMMI

© 2025 SNMMI

Powered by HighWire